3 New Strong Buy Ratings from Top-Rated Analysts: 04/03/2026

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Tenet Healthcare (THC) — 15 analysts agree: this healthcare giant is a Strong Buy
• Nature's Sunshine Products (NATR) — Record-breaking results from the #1 Zen Rated stock
• AnaptysBio (ANAB) — Major spin-off and $100M buyback fuel analyst excitement

P.S. Want more trending tickers? Check out our latest video about quantum stocks poised to explode.

A note from our sponsors...

1. Tenet Healthcare Corp (NYSE: THC)

With earnings momentum building ahead of its May 5th report, diversified healthcare player THC is turning heads on Wall Street as one of the highest-rated stocks in the A-rated Medical Care Facility industry.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $188.71 — get current quote

Max 1-year forecast: $288.00

Why we're watching:

• Analyst support: THC commands strong Street backing among the analysts we track, with 12 Strong Buy and 3 Buy ratings from 15 analysts. See the ratings
• Truist Securities' David S Macdonald (a top 11% rated analyst) maintains his Strong Buy rating following meetings with management, emphasizing the company's strong fundamentals and positive growth prospects in the healthcare sector.
• UBS analyst A.J. Rice (top 12%) continues to highlight the company's strong demand for healthcare services and expansion plans in underserved markets, supporting the bullish thesis.
• Industry ranking context: THC is currently the 6th highest-rated stock out of 39 in the Medical Care Facility industry, which has an Industry Rating of A.
• Zen Rating highlights: As a Strong Buy (A) rated stock, THC ranks in the top 5% of stocks we track — a category that has historically delivered 32.52% annual returns. 
• Component Grades: The stock earns particularly strong marks for Value and Sentiment, with solid Financials and Momentum scores reflecting both fundamental strength and market enthusiasm. (See all 7 Zen Component Grades here)

2. AnaptysBio Inc (NASDAQ: ANAB)

With the First Tracks Biotherapeutics spin-off set for April 20th and a freshly authorized $100 million stock repurchase plan, this biotech company is entering a transformative stretch that has Wall Street paying close attention.

Zen Rating: Buy (B) — see full analysis

Recent Price: $55.81 — get current quote

Max 1-year forecast: $100.00

Why we're watching:

• Analyst support: ANAB commands strong backing with 5 Strong Buy and 2 Buy ratings from 7 covering analysts. See the ratings
• For instance, Barclays analyst Etzer Darout (a top 2% rated analyst) maintains his Strong Buy rating with a $79 price target (40%+ upside), believing that AnaptysBio's innovative approaches will drive success in an evolving market, emphasizing that competitive advantages are growing.
• Guggenheim's Yatin Suneja (top 3%) sets the Street-high $100 price target (+80.54% upside), with insights suggesting a bullish future based on data from recent trials showing that innovations are driving growth and data supports potential market share gains. 
• Industry ranking context: ANAB is currently the 13th highest-rated stock in the Biotech industry. See all biotech stocks here.
• Zen Rating highlights: ANAB currently earns a Zen Rating of B (Buy), which means it ranks in the top 20% of stocks we track based on a careful 115-factor review. Considering the volatility of the biotech industry, this is pretty impressive.
• Component Grades: ANAB demonstrates balanced strength with a Momentum grade of B and Sentiment grade of B, though the Safety grade of F reflects the typical risk profile of clinical-stage biotech companies, while Financials earn a B grade supported by a strong 45.8% profit margin. (See all 7 Zen Component Grades here)

3. Natures Sunshine Products (NASDAQ: NATR)

Despite operating in a challenging D-rated Food industry, natural food and wellness company NATR shines as the 2nd highest-rated stock in the sector — backed by record-breaking results and unanimous Strong Buy ratings from covering analysts.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $23.94 — get current quote

Max 1-year forecast: $33.00

Why we're watching:

• Analyst support: NATR enjoys unanimous support and Strong Buy ratings among the analysts we track issuing ratings. See the ratings
• For example, Canaccord Genuity's Susan Anderson (a top 13% rated analyst) maintains her Strong Buy rating and projected 37% upside price target, highlighting NATR's potential to outperform the industry due to its unique positioning and branding strategy, with strategic partnerships expected to enhance distribution. 
• NATR is a valued addition to our Zen Investor portfolio, where Editor-in-Chief Steve Reitmeister rates the stock a Buy and praises its solid fundamentals and excellent historical track record. 
• The company's earnings report beat revenue estimates by 7.76% with year-over-year revenue growth of 7.76%, while management remains optimistic about upcoming trends in health and wellness that may favor their product line.
• Industry ranking context: NATR is currently the 2nd highest-rated stock in the Food industry, though as previously noted, the industry is not well-rated. (Here’s why Industry Ranking matters.)
• Zen Rating highlights: NATR ranks in the top 1% of stocks we track based on fundamentals — a fact that shouldn’t be ignored despite the ailing industry. Its overall rating is A (Strong Buy).
• Component Grades: Sentiment earns an excellent A grade, while Value and Financials earn above-average Bs. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.